Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Dara, len & dex for newly-diagnosed myeloma

Shaji Kumar • 11 Dec 2020
ASH 2020
Multiple Myeloma Antibodies Daratumumab Dexamethasone Lenalidomide
MAIA

Shaji Kumar, MD, Mayo Clinic, Rochester, MN presents the results of the Maia study (NCT02252172), a Phase III comparison of daratumumab, lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly-diagnosed multiple myeloma that are ineligible for autologous stem cell transplantation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Shaji Kumar

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
1:18
Overview of the updated NCCN Clinical Practice Guidelines for systemic AL amyloidosis
Shaji Kumar • 11 May 2023
1:26
Evaluating the efficacy of ixazomib, cyclophosphamide and dexamethasone in amyloidosis
Shaji Kumar • 11 May 2023

Related Videos

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals